Laboratory Co. of America Holdings (NYSE:LH) Shares Purchased by Jag Capital Management LLC

Jag Capital Management LLC boosted its position in Laboratory Co. of America Holdings (NYSE:LH) by 1.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,015 shares of the medical research company’s stock after purchasing an additional 221 shares during the period. Jag Capital Management LLC’s holdings in Laboratory Co. of America were worth $3,214,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Commerzbank Aktiengesellschaft FI acquired a new stake in Laboratory Co. of America in the fourth quarter worth approximately $211,000. Charles Schwab Investment Management Inc. lifted its position in Laboratory Co. of America by 9.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 599,551 shares of the medical research company’s stock worth $137,489,000 after purchasing an additional 50,165 shares during the period. Steward Partners Investment Advisory LLC lifted its position in shares of Laboratory Co. of America by 13.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 733 shares of the medical research company’s stock valued at $168,000 after acquiring an additional 86 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Laboratory Co. of America during the 4th quarter valued at $52,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Laboratory Co. of America by 28.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,620 shares of the medical research company’s stock valued at $601,000 after acquiring an additional 584 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Co. of America Trading Up 1.2 %

NYSE LH opened at $254.01 on Tuesday. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $21.26 billion, a PE ratio of 28.80, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. The firm’s fifty day simple moving average is $241.72 and its 200-day simple moving average is $232.98.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. As a group, sell-side analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.13%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s payout ratio is 32.65%.

Insiders Place Their Bets

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the sale, the director now directly owns 12,722 shares in the company, valued at $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the sale, the executive vice president now owns 2,171 shares of the company’s stock, valued at $545,572.30. This trade represents a 37.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,661 shares of company stock valued at $2,119,118 over the last three months. 0.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Bank of America increased their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. StockNews.com upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Barclays cut their price objective on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a research report on Friday, February 7th. Morgan Stanley increased their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Finally, Piper Sandler increased their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Laboratory Co. of America currently has an average rating of “Moderate Buy” and a consensus price target of $265.75.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.